curacle co., ltd. Logo

curacle co., ltd.

Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.

365270 | KO

Overview

Corporate Details

ISIN(s):
KR7365270008
LEI:
Country:
South Korea
Address:
서울특별시 서초구 효령로 23-1, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Curacle Co., Ltd. is a biopharmaceutical company established in 2016, specializing in the research and development of innovative drugs for intractable diseases. The company focuses on conditions arising from vascular damage and the aging process, with a particular emphasis on treatments for diseases like diabetes and stroke. Leveraging its unique research and platform technologies, Curacle develops a pipeline of new drug candidates to address significant unmet medical needs. The company aims to create treatments with high commercial potential and marketability.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.1 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.3 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.4 KB
2025-09-09 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 113.1 KB
2025-09-09 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (주주배정후 실권주 일반공모)
Korean 8.1 KB
2025-09-09 00:00
Share Issue/Capital Change
[기재정정]증권발행실적보고서
Korean 121.2 KB
2025-09-08 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 10.3 KB
2025-09-03 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 9.7 KB
2025-08-28 00:00
Share Issue/Capital Change
유상증자최종발행가액확정
Korean 11.4 KB
2025-08-28 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 41.6 KB
2025-08-28 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 260.5 KB
2025-08-28 00:00
Prospectus
[기재정정]투자설명서
Korean 2.2 MB
2025-08-13 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.08)
Korean 2.4 MB
2025-08-12 00:00
Interim Report
반기보고서 (2025.06)
Korean 939.8 KB

Automate Your Workflow. Get a real-time feed of all curacle co., ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for curacle co., ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for curacle co., ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

JETEMA Co.,Ltd. Logo
Research-driven developer of aesthetic toxins, dermal fillers, and threads.
South Korea
216080
Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.
South Korea
007370
JOHNSON & JOHNSON Logo
Develops innovative medicines and medical technologies for complex diseases and personalized care.
United States of America
JNJ
Journey Medical Corp Logo
A pharmaceutical firm commercializing prescription drugs and generics for dermatology.
United States of America
DERM
JUPITER NEUROSCIENCES, INC. Logo
Pharma firm developing resveratrol treatments for neuroinflammation and rare diseases.
United States of America
JUNS
JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea
234080
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel
KDST
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556

Talk to a Data Expert

Have a question? We'll get back to you promptly.